Back to Research

Organization profile

InVirtuoLabs

InVirtuoLabs is a Swiss biotechnology company that combines generative artificial intelligence with physics-based molecular simulations to accelerate the discovery of small-molecule therapeutics. The company's platform, InVirtuoGEN, explores vast chemical spaces to design and optimize novel drug candidates for metabolic, neurological, and rare diseases with high precision and reduced development costs.

Lausanne, SwitzerlandFounded 2023

Overview

1. Executive Summary (Confidence: High)

InVirtuoLabs is at the forefront of the AI-driven drug discovery revolution, merging chemical language models with atomic-level physical simulations to solve the "Eroom's Law" of declining pharmaceutical productivity.[2] Founded in Lugano in early 2024, the organization has developed a full-stack computational platform, "InVirtuoPlatform," which has significantly outperformed industry benchmarks, including NVIDIA’s GenMol, in the generation of viable drug-like compounds.[4]

The company follows a dual-track strategy: developing its own proprietary pipeline of drug candidates for high-incidence metabolic and rare neurological disorders, while simultaneously forming strategic R&D collaborations with established pharmaceutical firms like Helsinn Healthcare.[5] In early 2025, InVirtuoLabs closed a €2.85 million seed round and was subsequently awarded a €2.3 million Eurostars grant to lead the NEUROSPARK project for neurodegenerative research.[3] By halving development times and doubling clinical success rates, InVirtuoLabs is positioned as a critical infrastructure provider in the modern longevity and biotech landscape.[2]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.